Physician profile
Terrence F Swade
NPI 1699847202
$368,735.84
in general payments reported to CMS, 2019-2025
62 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $35K · 2021: $36K · 2022: $61K · 2023: $74K · 2024: $58K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Consulting Fee: $22K · Food and Beverage: $20K · Honoraria: $16K · Travel and Lodging: $7,545 · Education: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,353.69 |
| Consulting Fee | $21,735.00 |
| Food and Beverage | $19,784.76 |
| Honoraria | $15,870.00 |
| Travel and Lodging | $7,544.95 |
| Education | $412.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $204,250.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $85,645.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $41,645.30 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals Lp | $11,131.58 | 2019-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $3,427.39 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $2,986.74 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $1,931.25 | 2019-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $1,741.17 | 2021-2025 | |
| Dexcom, INC. | $1,672.59 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Corcept Therapeutics | $1,619.75 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,546.82 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $1,319.31 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $1,006.48 | 2021-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $910.24 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $750.01 | 2019-2025 | Synthroid |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $483.78 | 2019-2023 | Steglatro |
| Antares Pharma, INC. | $483.40 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Aimmune Therapeutics, INC. | $440.09 | 2024-2025 | Zenpep |
| Radius Health, INC. | $405.96 | 2019-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $325.14 | 2020-2025 | Unithroid |
| Abbott Laboratories | $322.87 | 2019-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $311.36 | 2019-2024 | Tirosint, Licart, Licart |
| Insulet Corporation | $286.28 | 2019-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $243.06 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $242.97 | 2023-2025 | |
| Amryt Pharma Holdings Ltd | $238.31 | 2022-2023 | Mycapssa |
| Beta Bionics, INC. | $219.64 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic Minimed, INC. | $198.82 | 2019-2020 | |
| Medtronic, INC. | $196.34 | 2021-2024 | Minimed 780g |
| Intuity Medical INC | $196.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $168.70 | 2019-2020 | |
| Sequel Med Tech, LLC | $163.13 | 2025 | Twiist |
| Eusa Pharma (US) LLC | $156.46 | 2022 | |
| Valeritas, INC. | $155.46 | 2019 | |
| Verity Pharmaceuticals INC. | $140.56 | 2024-2025 | Tlando |
| Ascendis Pharma Endocrinology INC | $139.35 | 2024-2025 | Yorvipath |
| Shire North American Group INC | $131.45 | 2019 | |
| Zealand Pharma US, INC. | $129.62 | 2020-2022 | |
| Cequr Corporation | $129.57 | 2023-2024 | Cequr Simplicity |
| Embecta Corp. | $125.43 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Astellas Pharma US INC | $100.80 | 2023-2024 | Veozah, Myrbetriq |
| Halozyme INC | $86.30 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $74.38 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.85 | 2020 | |
| Arbor Pharmaceuticals, INC. | $69.10 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $67.72 | 2019-2021 | |
| Chiesi USA, INC. | $65.85 | 2024-2025 | Mycapssa |
| Becton, Dickinson and Company | $64.53 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.71 | 2020-2023 | Cycloset |
| Esperion Therapeutics, INC. | $62.14 | 2020-2021 | |
| Madrigal Pharmaceuticals | $60.96 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $51.44 | 2025 | Arexvy, Shingrix |
| Janssen Scientific Affairs, LLC | $49.90 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $46.26 | 2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $38.13 | 2025 | NP Thyroid 60 |
| Theracosbio, LLC | $34.56 | 2023-2024 | Brenzavvy |
| Lifescan, INC. | $28.78 | 2019-2021 | |
| Pfizer INC. | $22.20 | 2023 | |
| Kyowa Kirin, INC. | $21.43 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.87 | 2019 | |
| Vistapharm, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Swade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.